Authors

Latest:

Making an Impact in the Fight Against GU Cancers as Scientist, Physician, and Teacher

Long before Dean F. Bajorin, MD, would travel the world as a renowned expert in genitourinary cancers—presenting at international conferences, working with major task forces, and changing the paradigms of care for patients in every corner of the globe—he began with a decidedly shorter journey: to college.

Deanna J. Attai, MD

Latest:

Dr. Attai on the Challenges With Implementing Survivorship Care Plans

Deanna J. Attai, MD, assistant clinical professor of surgery at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), breast surgeon at UCLA Health, discusses studies exploring the challenges with survivorship care plan implementation for patients with cancer in an interview during the 2017 ASCO Annual Meeting.

Deborah A. Bradley, MD

Latest:

Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer

Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.

Deborah Abrams Kaplan

Latest:

Addressing AYA Cancer Requires a Tailored Approach to Practice

Investigators have expanded the scientific understanding of cancer in the adolescent young adult patient population over the past decade. However, unmet needs remain in establishing treatment standards, addressing unique survivorship challenges, and providing a framework for patients to reference as they navigate their cancer journey.

Deborah Krakow, MD

Latest:

Dr. Krakow on Genetic Testing in Ovarian Cancer

Deborah Krakow, MD, professor and chair, Department of Obstetrics and Gynecology, professor of Orthopaedic Surgery and Human Genetics, University of California, Los Angeles, discusses genetic testing in patients with ovarian cancer.

Debra Patt, MD

Latest:

Dr. Patt on the Role of Sacituzumab Govitecan in TNBC

Debra Patt, MD, PhD, MBA, breast medical oncologist, vice president of Texas Oncology, highlights the role of sacituzumab govitecan-hziy in triple-negative breast cancer.

Debra Patt, MD, MPH, MBA

Latest:

Federal Indecisiveness Belies Significant Changes in Medicaid Policy State by State

Today’s healthcare landscape is rapidly evolving, with many trends emerging and policy changes under consideration that have far-reaching implications for cancer care.

Debra Wood

Latest:

Mayo Study Characterizes Pembrolizumab-Induced Thyroiditis

Abnormal thyroid function tests were reported in up to 15% of patients treated with the PD-1 inhibitor pembrolizumab.

Debu Tripathy, MD,

Latest:

Dr Tripathy on Real-World HER2 Testing and CDK4/6 Inhibitor Use in HER2+ Breast Cancer

Debu Tripathy, MD, discusses real-world strategies for CDK4/6 inhibitor use and the importance of HER2 testing in HER2-positive metastatic breast cancer.

Debu Tripathy, MD, MD Anderson Cancer Center

Latest:

“HER2 Breast Cancer Talk”: A Review of Data from the SABCS 2020 Virtual Symposium

Debu Tripathy, MD, The University of Texas MD Anderson Cancer Center

Latest:

Dr. Tripathy on the Evolving Treatment Landscape of HER2+ Breast Cancer

Debu Tripathy, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.

Debu Tripathy, MD, University of Texas MD Anderson Cancer Center

Declan Walsh, MSc, FACP, FRCP

Latest:

Declan Walsh, MSc, FACP, FRCP, on the Under-Diagnosis of Malnutrition

Declan Walsh, MSc, FACP, FRCP, director, 2014 MASCC/ISOO International Symposium, discusses the under-diagnosis of malnutrition in palliative medicine.

Deepak A. Kapoor, MD

Latest:

Dr. Kapoor on LUGPA's Legislative Advocacy

Deepak A. Kapoor, MD, chairman and CEO of Integrated Medical Professionals and Large Urology Group Practice Association's (LUGPA's) chairman of health policy, discusses LUGPA's legislative advocacy efforts.

Deepika Narasimha, MD1, Anthony Jarkowski, III, PharmD2,and Nikhil I. Khushalani*, MD1,3

Deepu Madduri, MD

Latest:

CAR T-Cell Therapy for Multiple Myeloma: What Community Oncologists Need to Know

The emergence of cellular-based therapies represents a major opportunity to improve outcomes in the heavily pretreated and refractory myeloma population.

Deirdre J. Cohen, MD

Latest:

Dr. Deirdre Cohen on Emerging Agents in Gastric Cancer

Deirdre J. Cohen, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses emerging agents for the treatment of patients with gastric cancer.

Delshad Ahmad, MD

Latest:

Hemophagocytic Lymphohistiocytosis in a Patient With Nodular Lymphocyte–Predominant Hodgkin Lymphoma: A Case Report

This is the first case report of hemophagocytic lymphohistiocytosis complicating a nodular lymphocyte–predominant Hodgkin lymphoma in an adult treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.

Delvys Rodriguez-Abreu, MD

Latest:

Dr. Rodriguez-Abreu on Updated Results From the KEYNOTE-189 Trial in NSCLC

Delvys Rodriguez-Abreu, MD, discusses findings from the final analysis of the phase 3 KEYNOTE-189 study in metastatic nonsquamous non–small cell lung cancer.

Demmie Aguilar

Latest:

Demmie Aguilar on Selecting a Clinical Trial Site

Demmie Aguilar, research coordinator, Clinical Research Division, Regional Cancer Care Associates, LLC, Central Jersey Division, discusses the qualities pharmaceutical companies look for when selecting a clinical trial site.